Trial Profile

A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8266 in Elderly Subjects With Hypertension

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 8266 (Primary)
Indications Essential hypertension
Focus Adverse reactions; Therapeutic Use
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

25 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
25 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
13 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com